Background and Rationale

Recent surges in cancer incidence are intensifying pressure to accelerate new‑drug development. The U.S. FDA recognizes that approval processes confined to a single country significantly increase time and cost. Consequently, there is a growing need for international collaboration to improve efficiency.

Simultaneous Review Framework

The Orbis Project is designed so that regulatory agencies in multiple countries review a new‑drug application concurrently. This enables sponsors to obtain approval in a single step rather than awaiting separate reviews in each jurisdiction. Simultaneous review contrasts with the traditional sequential approach and delivers substantial time savings.

Significance of International Partnerships

Led by the FDA Oncology Center of Excellence (OCE) and conducted in partnership with the U.K. MHRA, Canada’s Health Canada, and others, this collaboration harmonizes regulatory standards and facilitates data sharing, allowing faster patient access worldwide. Historically, national regulatory barriers have been major obstacles; today, collaborative models are becoming the norm.

Future Scenarios and Challenges

If successful, simultaneous review could be expanded to additional therapeutic areas. However, challenges remain, including data security and differing local regulatory requirements. Ongoing dialogue and transparent procedures will be essential to maximize patient benefits.